Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia

Blood

Volumn 93, Issue 8, 1999, Pages 2671-2678

  Hogarth, Linda A ^a   Hall, Andrew G ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN BCL 2;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DRUG SENSITIVITY; HUMAN; IMMUNOBLOTTING; KARYOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; RECURRENCE RISK; RELAPSE; TREATMENT OUTCOME;

EID: 0033560819     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.8.2671.408k26_2671_2678     Document Type: Article

References (58)

1. Hickman JA: Apoptosis and chemotherapy resistance. Eur J Cancer 32A:921, 1996
2. Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 89:1845, 1997
3. Reed JC, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, Aimé-Sempé C, Bodrug S, Kitada S, Hanada M: BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60:23, 1996
4. Yang E, Korsmeyer SJ: Molecular thanatopsis: A discourse on the BCL2 family and cell death. Blood 88:386, 1996
5. Chen Levy Z, Nourse J, Cleary ML: The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol Cell Biol 9:701, 1989
6. Cleary ML, Smith SD, Sklar J: Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47:19, 1986
7. Tsujimoto Y, Croce CM: Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83:5214, 1986
8. Pezzella F, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY: Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 137:225, 1990
9. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC: Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 4:71, 1994
10. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyes F, Gaulard P: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 87:265, 1996
11. Reed JC: Bcl-2 family proteins: Regulators of chemoresistance in cancer. Toxicol Lett 82-83:155, 1995
12. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151, 1993
13. Lotem J, Sachs L: Control of sensitivity to induction of apoptosis in myeloid leukemic cells by differentiation and bcl-2 dependent and independent pathways. Cell Growth Differ 5:321, 1994
14. Reed JC, Kitada S, Takayama S, Miyashita T: Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 5:61, 1994
15. Fisher TC, Milner AE, Gregory CD, Jackman AL, Aherne GW, Hartley JA, Dive C, Hickman JA: bcl-2 Modulation of apoptosis induced by anticancer drugs: Resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 53:3321, 1993
16. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J: bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 53:4251, 1993
17. Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ, Kohn KW: Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 53:1853, 1993
18. Jacobson MD: Apoptosis: Bcl-2-related proteins get connected. Curr Biol 7:R277, 1997
19. Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3:614, 1997
20. Hsu SY, Kaipia A, McGee E, Lomeli M, Hsueh AJ: Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. Proc Natl Acad Sci USA 94:12401, 1997
21. Farrow SN, Brown R: New members of the Bcl-2 family and their protein partners. Curr Opin Genet Dev 6:45, 1996
22. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, Reed JC: Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 91:991, 1998
23. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33:451, 1976
24. Sobol RE, Royston I, LeBien TW, Minowada J, Anderson K, Davey FR, Cuttner J, Schiffer C, Ellison RR, Bloomfield CD: Adult acute lymphoblastic leukemia phenotypes defined by monoclonal antibodies. Blood 65:730, 1985
25. Duke RC, Cohen JJ: Morphological and biochemical assays of apoptosis, in Coligan JE, Kruisbeck AM, Margulies DH, Shevack EM, Strober W (eds): Current Protocols in Immunology. New York, NY, Wiley, 1991, p 3.17
26. Terstappen LWMM, Meiners H, Loken MR: A rapid sample preparation technique for flow cytometric analysis of immunofluorescence allowing absolute enumeration of cell subpopulations. J Immunol Methods 123:103, 1989
27. Dhut S, Gibbons B, Chaplin T, Young BD: Establishment of a lymphoblastoid cell line, SD-1, expressing the p190 bcr-abl chimaeric protein. Leukemia 5:49, 1991
28. Andersson LC, Nilsson K, Gahmberg CG: K562 - A human erythroleukemic cell line. Int J Cancer 23:143, 1979
29. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T-4. Nature 227:680, 1970
30. Hall AG, Matheson E, Hickson ID, Foster SA, Hogarth L: Purification of an a class glutathione S-rransferase from melphalan-resistant Chinese hamster ovary cells and demonstration of its ability to catalyze melphalan-glutathione adduct formation. Cancer Res 54:3369, 1994
31. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ: Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 10:456, 1996
32. Campos L, Rouault J-P, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud J-P, Guyotat D: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091, 1993
33. Campos L, Sabido O, Sebban C, Charrin C, Bertheas MF, Fière D, Guyotat D: Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia. Leukemia 10:434, 1996
34. Gala JL, Vermylen C, Cornu G, Ferrant A, Michaux JL, Philippe M, Martial P: High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with the prognosis. Ann Hematol 69:17, 1994
35. Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, Behm FG, Aricò M, Campana D: Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 87:1140, 1996
36. Uckun FM, Yang ZW, Sather H, Steinherz P, Nachman J, Bostrom B, Crotty L, Sarquis M, Ek O, Zeren T, Tubergen D, Reaman G, Gaynon P: Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: A children's cancer group study. Blood 89:3769, 1997
37. Wolowiec D, Mekki Y, Ffrench P, Manel AM, Bertrand Y, Rimokh R, Philippe N, Bryon PA, Ffrench M: Differential expression of cell proliferation regulatory proteins in B- and T-lineage acute lymphoblastic leukaemias. Br J Haematol 95:518, 1996
38. Salomons GS, Brady HJM, Verwijs-Janssen M, Van den Berg JD, Hart AAM, Van den Berg H, Behrendt H, Hählen K, Smets LA: The Baxα:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int J Cancer 71:959, 1997
39. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell 74:609, 1993
40. Yin X-M, Oltvai ZN, Korsmeyer SJ: BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369:321, 1994
41. Brady HJM, Salomons GS, Bobeldijk RC, Berns AJM: T cells from baxa transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53. EMBO J 15:1221, 1996
42. Stoetzer OJ, Nüssler V, Darsow M, Gullis E, Pelka-Fleischer R, Scheel U, Wilmanns W: Association of bcl-2, bax, bcl-xL and inteuleukin-1β-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia 10:S18, 1996 (suppl 3)
43. Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 12:1055, 1996
44. Pepper C, Hoy T, Bentley DP: Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 76:935, 1997
45. Binder C, Marx D, Binder L, Schauer A, Hiddemann W: Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer. Ann Oncol 7:129, 1996
46. Marx D, Binder C, Meden H, Lenthe T, Ziemek T, Hiddemann T, Kuhn W, Schauer A: Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res 17:2233, 1997
47. Brady HJ, Gil-Gomez G, Kirberg J, Berns AJ: Bax alpha perturbs T cell development and affects cell cycle entry of T cells. EMBO J 15:6991, 1996
48. Borner C: Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem 271:12695, 1996
49. Mazel S, Burtrum D, Petrie HT: Regulation of cell division cycle progression by bcl-2 expression: A potential mechanism for inhibition of programmed cell death. J Exp Med 183:2219, 1996
50. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY: bcl-2 Protein in non-small-cell lung carcinoma. N Engl J Med 329:690, 1993
51. Sinicrope FA, Hart J, Michelassi F, Lee JJ: Prognostic value of bcl-2 oncoprotein expression in stage II colon cancer. Clin Cancer Res 1:1103, 1995
52. Pui C-H, Behm FG, Singh B, Schell MJ, Williams DL, Rivera GK, Kalwinsky DK, Sandlund JT, Crist WM, Raimondi SC: Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 75:174, 1990
53. Ito T, Deng X, Carr B, May WS: Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 272:11671, 1997
54. Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau VJ: Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem 272:19022, 1997
55. Haldar S, Jena N, Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92:4507, 1995
56. Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C, Gillieron C, Boschert U, Vial-Knecht E, Martinou JC, Arkinstall S: Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J Biol Chem 272:25238, 1997
57. Meijerink JPP, Smetsers TFCM, Slöetjes AW, Linders EHP, Mensink EJBM: Bax mutations in cell lines derived from hematological malignancies. Leukemia 9:1828, 1995
58. Meijerink JPP, Mensink EJBM, Wang K, Sedlak TW, Slöetjes AW, De Witte T, Waksman G, Korsmeyer SJ: Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 91:2991, 1998